Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68001-0571-41 68001-0571 Bendamustine hydrochloride Bendamustine hydrochloride 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Sep 15, 2023 Sep 16, 2023 In Use
00009-7529-03 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jun 14, 1996 In Use
59923-0714-02 59923-0714 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Mar 1, 2019 In Use
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 5.0 mg/mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov 14, 2022 In Use
50742-0438-10 50742-0438 arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 15, 2018 In Use
00143-9548-10 00143-9548 Doxorubicin Hydrochloride Adriamycin 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 1, 1996 In Use
00703-4434-11 00703-4434 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb 28, 2008 Mar 31, 2019 No Longer Used
25021-0802-10 25021-0802 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous Jan 15, 2010 Dec 31, 2014 No Longer Used
50742-0428-02 50742-0428 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sep 7, 2017 Apr 30, 2021 In Use
55648-0661-01 55648-0661 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jun 30, 2008 In Use
00013-2596-20 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Mar 11, 2024 In Use
23155-0884-31 23155-0884 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug 31, 2023 In Use
70860-0783-10 70860-0783 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Mar 15, 2021 Jul 31, 2024 No Longer Used
66758-0054-02 66758-0054 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 2, 2011 May 2, 2011 In Use
00143-9548-01 00143-9548 Doxorubicin Hydrochloride Adriamycin 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 1, 1996 In Use
00069-9321-22 00069-9321 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec 22, 2011 Dec 31, 2017 No Longer Used
49315-0005-10 49315-0005 Arsenic trioxide Arsenic trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 14, 2018 In Use
47335-0151-40 47335-0151 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 19, 2008 Jun 30, 2016 No Longer Used
70121-1222-01 70121-1222 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan 19, 2018 In Use
14335-0471-10 14335-0471 Cyclophosphamide for Injection Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan 3, 2025 In Use
68001-0468-36 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec 9, 2020 In Use
16729-0332-05 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Nov 30, 2026 In Use
00143-9307-01 00143-9307 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan 12, 2018 In Use
00310-4611-50 00310-4611 Durvalumab Imfinzi 500.0 mg/10mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 1, 2017 In Use

Found 12159 results — Export these results